Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
    • Expanded Access
  • Partnering
  • Careers
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Publications
  • Presentations
  • Email Alerts
Jul 12, 2016 9:36am EDT

Sapience Therapeutics Completes $22.5 Million Series A Financing

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
RSS
© 2022 Sapience Therapeutics, Inc. All Rights Reserved.
linkedin
Privacy Policy Disclaimer Sitemap